Drugs for Coagulation Disorders Flashcards

1
Q

Factors XII –> XIIa is the start of which pathway? 1)
It is activated by exposure of 2);
Other necessary components for this pathway to initiate are 3)

A

1) INTRINSIC
2) Subendothelial collagen (SEC)
3) Prekallikrein (PK); High Molecular Weight Kininogen (HK)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Factor VII–> VIIa is the start of which pathway? 1)

it is activated by 2)

A

1) extrinsic

2) Tissue factor (TF) also called thromboplastin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Hemophilia A vs. B

A

(1) A is caused by a
deficiency of factor VIII.
(2) B is caused by a
deficiency of factor IX.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q
von Willebrand factor is
the carrier molecule for
1)  
protecting it from
degradation and removal
A

1) circulating factor VIII

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

A deficiency in 1) reduces the half-life of factor VIII and decrease plasma factor VIII levels.

A

1) von Willebrand Factor

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Platelet membrane receptors include the 1) , binding to collagen (C);

2) binding von Willebrand factor (vWF);
3) binds fibrinogen and other macromolecules.

A

1) glycoprotein (GP) Ia receptor
2) GP Ib receptor
3) GP IIb/IIIa

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Antiplatelet prostacyclin
(PGI2) is released from
the 1)

A

1) endothelium

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Aggregating substances

released from the degranulating platelet include 1)

A
adenosine diphosphate (ADP), 
thromboxane A2 (TXA2), 
and serotonin (5-HT)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

vWF promotes platelet adhesion by interacting with 1);

A deficiency of vWF reduces 2)

A

1) GP Ib receptor on PLATELETS

2) platelet adhesion

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

vWF plays a dual role in hemostasis affecting both platelet adhesion and coagulation; explain.

A

affects platelets adhesion–> Gp1b receptors on platelets;

affect coagulation–> vWF inc. half life of Factor VIII

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Fibrinolysis:

Plasmin is generated by the proteolytic cleavage of 1) , a plasma protein that is synthesized in the 2)

A

1) plasminogen

2) liver

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Fibrinolysis

The proteolytic cleavage of plasminogen is catalyzed by 1) , which is synthesized and secreted by the 2)

A

1) tissue plasminogen activator
(t-PA)
2) endothelium

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

What does the endothelium secrete?

What does endothelium store?

A

Secretes Tissue plasminogen activator;
vWF
PGI2 (antiplatelet);
Stores vWF-Factor VIII complex (this is where desmpressin acts)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Fibrinolysis:
Plasmin exerts its anticoagulant effect by proteolytically cleaving 1)
into 2)

A

1) fibrin

2) fibrin degradation products

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Hemophilia
The bleeding manifestations include 1), 2) hemorrhages, and excessive bleeding after
surgery or trauma.

A

1) palpable ecchymoses, hemarthroses

(bleeding into joint spaces),

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Hemophilia

severity of bleeding correlates with the degree of deficiency of factor 1)

A

1) VIII or IX

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Hemophilia Disease severity:
Severe–> 1)
Moderate–> 2)
Mild–> 3)

A

1) Frequent spontaneous hemorrhages and
hemarthroses
2) Excessive bleeding following mild trauma
3) Few symptoms or excessive bleeding only
after significant trauma or surgery

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Clinical manifestations are variable including asymptomatic, mucocutaneous
bleeding (e.g., epistaxis, gingival bleeding, menorrhagia), easy bruising, and
postoperative bleeding.

A

von Willebrand Disease

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

several types of von Willebrand Disease. Those that are

amenable to therapy include 1)

A

1) types 1, 2A, 2B, 2M, and 3

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

Systemic inflammation is associated with systemic activation of coagulation; 1) is the most severe form. There are many diverse triggers for 1).

A

Disseminated intravascular coagulation (DIC)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

DIC leads to 1) in the microvasculature often with 2) as coagulation factors and platelets are consumed

A

1) fibrin clot formation

2) compensatory bleeding

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

Vitamin K is a 1) vitamin;
Vitamin K1 (2) is found in green leafy vegetables;
Vitamin K2 is produced by 3)

A

1) fat-soluble
2) phytonadione
3) bacteria in the large intestine

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

Vitamin K
a. Cofactor in the activation of 1)- without vitamin K
they remain inactive precursors
b. Also required for the active forms of 2)

A

1) factors II, VII, IX, and X

2) proteins C and S

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

Vitamin K deficiency

Causes bleeding as a result of marked deficiency of 1) referred to as 2).

A

1) factors II, VII, IX,
and X
2) vitamin K deficiency bleeding (VKDB)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

Occurs in newborns- the have limited 1) at birth since

transplacental passage is limited

A

1) vitamin K stores

refers to Vitamin K deficiency

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q

Vitamin K deficiency–> patients with 1) or malabsorption

A

1) poor nutrition

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
27
Q

Vitamin K absorption depends on 1) and 2) to create micelles;
thus, Diseases of the 3) can lead to malabsorption

A

1) bile acids
2) pancreatic enzymes
3) intestine or pancreas

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
28
Q

1) may sterilize the large intestine and prevent vitamin K2 production

A

1) Broad spectrum antibiotics

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
29
Q

Broad spectrum antibiotics may sterilize the large intestine and
prevent 1)

A

1) vitamin K2 production

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
30
Q

Plasma-derived Factor VIII:
Derived from plasma of thousands of donors and can
therefore 1)

A

1) potentially transmit disease

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
31
Q

Plasma-derived Factor VIII:
In an effort to make the product safer, donors are screened, plasma is tested for evidence of infection, and virus is reduced through 1) (e.g., dry heat, pasteurization, solvent detergent treatment)

A

1) purification and inactivation procedures

32
Q

Prion disease remains a concern as well as yet unidentified

viruses that currently used methods would not inactivate

A

Plasma-derived Factor VIII:

33
Q

Produced using recombinant DNA technology using cultured cells (Chinese hamster ovary cells or baby hamster kidney cells)

A

Recombinant factor VIII

34
Q

advantage of Recombinant factor VIII over plasma derived;

A

Because it is not derived from blood donations, the risk of

transmitting infections is low

35
Q

Recombinant factor VIII:
Produced using 1) using cultured cells (Chinese hamster ovary cells or baby hamster kidney cells) transfected with the human factor VIII gene.

A

1) recombinant DNA technology

36
Q

Factor VIII dosage for minor bleeding vs sustain a desired level;

A

administered as a single dose for

minor bleeding, or every 12 hours or by continuous infusion to sustain a desired level of factor VIII

37
Q

Primary prophylaxis (regular replacement therapy) with Factor VIII started at a young age in Hemophilia pts before onset of 1)

A

1) joint bleeding

38
Q

A/E Factor VIII replacement:

Formation of 1), anti-factor VIII antibodies (usually 2) subclass), which inhibit factor VIII activity

A

1) inhibitors

2) IgG

39
Q

Viral infection associated with use of plasma-derived products

A

Plasma derived Factor VIII

40
Q

Thrombophlebitis at the infusion site

A

Factor VIII replacement

41
Q

AE–>Bacterial contamination of the concentrate

A

Factor VIII replacement

42
Q

AE–> Catheter-related infections (often a central venous line is
necessary)

A

Factor VIII replacement

43
Q

Primary prophylaxis

a) Cost (very expensive

A

Factor VIII replacement

44
Q

Desmopressin causes release of 1) from endogenous 2) storage site

A

1) factor VIII and vWF

2) endothelial

45
Q

DDAVP (desmopressin):
Adequate for 1) in patients with mild hemophilia A. Treatment with DDAVP will not result in hemostasis
in patients with 2) or those who do not respond well.

A

1) minor bleeding episodes;

2) severe hemophilia A

46
Q

DDAVP (desmopressin) admin

A

Intranasal spray or intravenous administration

47
Q

(1) Facial flushing
(2) Has antidiuretic effects so can cause water retention and dilutional
hyponatremia

A

DDAVP (desmopressin)

48
Q

Hemophilia B treatment

A

Same as for factor VIII replacement except the product is factor IX.

49
Q

1) and 2) bind competitively to plasminogen

blocking the binding of plasminogen to fibrin and subsequent conversion to plasmin

A

1) Aminocaproic acid and tranexamic acid

50
Q

Clinical use: Inhibits clot lysis for treatment of oral bleeding because of the high concentration of fibrinolytic enzymes found in saliva

A

Antifibrinolytics–> Aminocaproic acid and tranexamic acid

51
Q

Treatment of inhibitors in hemophilia for Patients with a LOW inhibitor titer:

(1) High doses of the ____ can control bleeding
(2) ____ may be useful

A

specific factor;

Antifibrinolytics

52
Q

Treatment of inhibitors in hemophilia for Patient with a high inhibitor titer:
Treatment of bleeding episodes requires use of agents which 1)

A

1) bypass the factor to which the antibody is directed; usually against Factor VIII or XI;

53
Q

Treatment of inhibitors in hemophilia for Patient with a high inhibitor titer:
1) contain vitamin K-dependent factors II, VII, IX, and X,
activated factor VII and IX;

A

1) Prothrombin complex concentrate (PCC) and activated PCC (aPCC)

54
Q

PCC vs. aPCC

A

aPCC contains more of the

activated factors than PCC;

55
Q

Adverse effects

a) Pulmonary emboli
b) DVT
c) MI

A

Prothrombin complex concentrate (PCC) and activated PCC

aPCC

56
Q

Treatment of inhibitors in hemophilia for Patient with a high inhibitor titer:
Other option is 1)

A

1) Recombinant factor VIIa;

57
Q

Recombinant factor VIIa
i) Only active at site of tissue injury where 1) is
present thus low risk of 2)
ii) Not plasma-derived so low risk of 3)

A

1) tissue factor
2) systemic thrombotic effects
3) viral transmission

58
Q

Advantages of Recombinant Factor VIIa over PCC/aPCC to treat inhibitors in hemophilia patients with HIGH inhibitor titer

A

Recombinant factor VIIa

i) low risk of systemic thrombotic effects
ii) low risk of viral transmission;

Adverse effects of PCC/aPCC

a) Pulmonary emboli
b) DVT
c) MI

59
Q

Treatment of inhibitors in hemophilia:
1), which involves regular infusion of high doses of the factor to which the antibody is directed, may eradicate the inhibitor

A

1) Immune tolerance therapy

60
Q

Treatment of inhibitors in hemophilia:
1) are used as
adjuncts

A

1) Immunosuppressants (e.g., cyclophosphamide, prednisone)

61
Q

Therapy is costly, time-consuming and often requires placement of a
central venous line

A

Treatment of inhibitors in hemophilia:

62
Q

Pain management in Hemophilia:
Usually the cause of pain is 1) so controlling the 1) eases pain;
Chronic pain results from permanent joint changes thus use 2) or drugs for pain management that don’t affect platelet function such as 3)

A

1) bleeding
2) Intraarticular dexamethasone
3) Acetaminophen, opioid analgesics, and COX-2 inhibitor (celecoxib)

63
Q

Local measures including pressure, ice, and topical thrombin can control
superficial bleeding

A

General treatment of von Willebrand Disease

64
Q

Drug treatment of von Willebrand Disease:

Systemic therapy is used for bleeding that cannot be controlled in this manner and for prevention of bleeding during 1)

A

1) surgery.

65
Q

Drug treatment of von Willebrand Disease:
The goal is to correct platelet adhesion and coagulation defects by stimulating the release of 1) or by administering products
containing 2).

A

1) endogenous vWF

2) vWF and factor VIII

66
Q
Replacement therapy (plasma derived) in von
Willebrand Disease indication:
A

used in types 2B, 2M, and 3 von Willebrand Disease;
also types 1 or 2A who are
unresponsive to desmopressin

67
Q

in pts with types 1 or 2A who are

unresponsive to desmopressin; use:

A

replacement therpay

68
Q

Plasma-derived vWF-containing products (two types)
A) 1) factor VIII concentrates contain sufficient functional vWF or
B) Plasma-derived vWF/FVIII complex (human)

A

1) Virus-inactivated

69
Q

AE

a. Formation of inhibitors
b. Viral infection associated with use of plasma-derived products
c. Thrombophlebitis at the infusion site

A

Plasma-derived vWF-containing products

70
Q

Effective for patients with adequate endogenous stores of vWF including most patients with type I disease and some with type 2A.

A

Desmopressin

71
Q

If unrecognized and left untreated, DIC may lead to death as a result of 1)

A

1) hemorrhage or thrombosis

72
Q

Most important step in therapy is to treat the underlying disease (e.g.,
antibiotics and vasoactive agents in treatment of sepsis and shock).

A

Drug treatment of DIC

73
Q

Drug treatment of DIC:

Fresh frozen plasma replaces 1)(a bunch of things); used for bleeding problems

A

1) clotting factors, fibrinogen, protein S, protein C, and antithrombin

74
Q

in DIC patients where thrombosis predominates, use:

A

Heparin

75
Q

Vitamin K deficiency: use 1)

A

Phytonadione which is Vit K1;

76
Q

Infants usually receive an intramuscular injection at birth

A

Phytonadione–> for Vit. K dependent bleeding prophylaxis